ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 193 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2020. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,135,381 | +290.7% | 31,848 | +405.5% | 0.00% | – |
| Q2 2023 | $290,619 | +6.3% | 6,300 | +6.8% | 0.00% | -100.0% |
| Q4 2022 | $273,347 | -38.3% | 5,900 | -44.9% | 0.00% | 0.0% |
| Q3 2022 | $443,000 | -63.1% | 10,700 | -46.8% | 0.00% | -75.0% |
| Q2 2022 | $1,199,000 | -76.7% | 20,100 | -71.6% | 0.00% | -75.0% |
| Q1 2022 | $5,135,000 | +104.0% | 70,705 | +136.3% | 0.02% | +100.0% |
| Q4 2021 | $2,517,000 | +67.0% | 29,923 | +126.1% | 0.01% | +14.3% |
| Q1 2021 | $1,507,000 | -43.5% | 13,233 | -31.3% | 0.01% | -36.4% |
| Q4 2020 | $2,665,000 | +542.2% | 19,249 | +263.2% | 0.01% | +266.7% |
| Q2 2020 | $415,000 | -67.7% | 5,300 | -71.4% | 0.00% | -70.0% |
| Q1 2019 | $1,283,000 | +5245.8% | 18,500 | +8464.8% | 0.01% | – |
| Q4 2015 | $24,000 | +140.0% | 216 | +116.0% | 0.00% | – |
| Q3 2015 | $10,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |